The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension

A Non-Interventional, Post-Marketing Surveillance Phase IV Study to Asses the Efficacy and Safety of Telmisartan, With the Special Attention on the Influence of Telmisartan on Selected Metabolic Parameters of Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00471003

Acronym

METABOLIC

Enrollment

5448

Registered

2007-05-08

Start date

2006-09-30

Completion date

2009-11-30

Last updated

2010-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension

Brief summary

The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.

Interventions

DRUGPritor (Telmisartan , BAY68-9291)

Primary care hypertensive patients starting the therapy with Telmisartan

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age over 18 * Untreated or ineffectively treated arterial hypertension

Exclusion criteria

* Cholestatic disorders and severe hepatic failure * Allergy to telmisartan * Pregnancy and lactation period

Design outcomes

Primary

Measure	Time frame
Efficacy and safety of the treatment with telmisartan reported by the physician	At the both of planned control visits. (Approx. interval between visits 3 months)

Secondary

Measure	Time frame
Changes in metabolic parameters in telmisartan treated patients	At the both of planned control visits. (Approx. interval between visits 3 months)

Countries

Croatia, Poland, Slovakia, Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026